公开(公告)号：US5228445A

公开(公告)日：1993-07-20

申请号：US813383

申请日：1991-12-26

申请人： Charles Y. C. Pak ,  Peter Antich

发明人： Charles Y. C. Pak ,  Peter Antich

IPC分类号： A61B8/08

CPC分类号： A61B8/0875 ,  G01N2291/0258 ,  G01N2291/02827 ,  G01N2291/102 ,  G01N2291/269

摘要： The invention involves a treatment process for improving the intrinsic quality of bone in osteoporotic patients. This can reduce the frequency of spinal fractures by inducing formation of bone which is mechanically stronger than that which it replaces. The process preferably comprises: administering an enteral form of sodium fluoride to maintain an individual's serum fluoride level from about 100 to about 200 ng/ml with a circadian fluctuation of less than about 75 ng/ml, and dietarily supplementing said individual with absorbable calcium (preferably calcium citrate). In one embodiment, sodium fluoride administration is interrupted temporarily (for about 30 to about 60 days in a 13 or 14 month cycle) to prevent loss of fluoride effectiveness and avert impaired mineralization of bone. Calcium is preferably maintained by an enteral dose of about 400 mg calcium twice daily. A vitamin D preparation may also be administered to the individual to further enhance bone strengthening. As a method for assessing response, periodic noninvasive in vivo measurements of intrinsic bone quality are made by reflection ultrasound, and the treatment regimen is maintained, altered or discontinued based on clinical assessment of the results. In this way, clinical response to the treatment is evaluated to guide its continued application.

摘要翻译： 本发明涉及用于改善骨质疏松患者骨质量的治疗方法。 这可以通过诱导骨的形成来降低脊柱骨折的频率，该骨比机械地强于骨代替骨。 该方法优选包括：施用肠内形式的氟化钠以维持个体的血清氟化物水平为约100至约200ng / ml，昼夜波动小于约75ng / ml，并且用所述个体用可吸收的钙进行膳食补充（ 优选柠檬酸钙）。 在一个实施方案中，氟化钠施用暂时中断（在13或14个月周期中约30至约60天），以防止氟化物失效的丧失，并避免骨质矿化。 钙优选通过约400mg钙的肠内剂量每天维持两次。 还可以向个体施用维生素D制剂以进一步增强骨骼的强化。 作为评估反应的方法，通过反射超声进行固有骨质量的周期性非侵入性体内测量，并且基于结果的临床评估来维持，改变或停止治疗方案。 以这种方式，对治疗的临床反应进行评估以指导其继续应用。

公开(公告)号：US4966776A

公开(公告)日：1990-10-30

申请号：US412801

申请日：1989-09-27

申请人： Charles Y. C. Pak

发明人： Charles Y. C. Pak

IPC分类号： A61K31/19

CPC分类号： A61K31/19 ,  Y10S514/891

摘要： Methods and compositions useful for the treatment and prophylaxis of calcium renal stones in persons with hypocitraturia or undergoing allopurinol therapy are disclosed. The methods involve administering potassium citrate compositions to persons afflicted with or susceptible to calcium renal stone formations. A typical dosage scheme involves administering about 30 to 120 meq potassium citrate per day in divided doses. Such treatments are effective in dissolving existing calcium stones and preventing formation of new calcium stones. Moreover, the results of a comparative clinical assay indicate the potassium citrate is superior to sodium citrate in the treatment of uric acid lithiasis. Potassium citrate therapy averts calcium renal stone formation, a complication which is often associated with sodium citrate or sodium bicarbonate alkalinization therapy.

摘要翻译： 公开了用于治疗和预防患有hypoitraturia或正在进行别嘌呤醇治疗的患者中的钙肾结石的方法和组合物。 所述方法涉及将柠檬酸钾组合物施用于患有钙敏感性肾结石形成的患者或易受影响的人。 典型的剂量方案包括每天以分剂量施用约30至120毫克柠檬酸钾。 这种治疗有效地溶解现有的钙结石并防止形成新的钙结石。 此外，比较临床检验的结果表明柠檬酸钾在治疗尿酸结石时优于柠檬酸钠。 柠檬酸钾治疗可以避免钙肾结石形成，这种并发症通常与柠檬酸钠或碳酸氢钠碱化治疗相关。

公开(公告)号：US4883791A

公开(公告)日：1989-11-28

申请号：US99191

申请日：1987-09-21

申请人： Charles Y. C. Pak ,  Milan R. Uskokovic ,  Joseph E. Zerwekh

发明人： Charles Y. C. Pak ,  Milan R. Uskokovic ,  Joseph E. Zerwekh

IPC分类号： A61K31/59

CPC分类号： A61K31/59 ,  Y10S514/891

摘要： The invention is directed to a method in the treatment of hypercalcitriolemic disease states which comprises administering an effective amount of 25S,26-dihydroxycholecalciferol to a host in need of such treatment.

摘要翻译： 本发明涉及治疗高精氨酸症状的方法，其包括将有效量的25S，26-二羟基胆钙化甾醇施用于需要这种治疗的宿主。

公开(公告)号：US07052833B1

公开(公告)日：2006-05-30

申请号：US09339352

申请日：1999-06-23

申请人： Berenice Y. Reed-Gitomer ,  Charles Y. C. Pak

发明人： Berenice Y. Reed-Gitomer ,  Charles Y. C. Pak

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6883 ,  C12Q2600/156 ,  Y10S435/81

摘要： Disclosed is a region on human chromosome 1 that provides a genetic basis for absorptive hypercalciuria. The genes, proteins, and other biological materials provided are envisioned for use in diagnostic and therapeutic methods related to absorptive hypercalciuria and osteoporosis with hypercalciuria.

摘要翻译： 公开了人类染色体1上为吸收性高钙尿症提供遗传基础的区域。 提供的基因，蛋白质和其他生物材料被设想用于与吸收性高钙尿症和具有高钙尿症的骨质疏松症有关的诊断和治疗方法。

公开(公告)号：US5432200A

公开(公告)日：1995-07-11

申请号：US46013

申请日：1993-04-12

申请人： Neill B. Walsdorf ,  George Alexandrides ,  Charles Y. C. Pak

发明人： Neill B. Walsdorf ,  George Alexandrides ,  Charles Y. C. Pak

IPC分类号： A23L1/304 ,  A61K31/19 ,  C07C59/265

CPC分类号： A61K31/19 ,  A23L33/16 ,  C07C59/265

摘要： A method for supplementing dietary potassium, magnesium and citrate is disclosed that comprises orally administering an effective amount of potassium magnesium citrate in a single salt. Methods for decreasing urinary calcium and oxalate by the administration of potassium magnesium citrate in a single salt are also disclosed.

摘要翻译： 公开了一种补充膳食钾，镁和柠檬酸盐的方法，其包括在单一盐中口服施用有效量的柠檬酸钾钾。 还公开了通过在单一盐中施用柠檬酸钾钾来降低尿钙和草酸盐的方法。

公开(公告)号：US4921807A

公开(公告)日：1990-05-01

申请号：US148148

申请日：1988-01-26

申请人： Charles Y. C. Pak

发明人： Charles Y. C. Pak

IPC分类号： G01N1/28 ,  G01N33/483

CPC分类号： G01N1/28 ,  Y10S514/97 ,  Y10T436/10 ,  Y10T436/108331 ,  Y10T436/171538 ,  Y10T436/201666 ,  Y10T436/2525

摘要： A urine specimen is preserved from bacterial deterioration as to relative constituents by adding thymol. To the thymol-treated specimen, lithium-solution volume-marker is added, then is divided into two (first and second) separate portions. Thereupon, using the first portion, standard conventional measurements and/or analysis is conducted for total volume, pH/acidity, uric acid, citrate, sodium, and potassium. To the second portion, there is added boric acid and hydrochloric acid, followed by standard/conventional measurement and/or analysis for ammonium ion, citrate, calcium, magnesium, phosphorus, oxalate and sulfate. Thereafter the findings are charted and compared to controls.

摘要翻译： 通过添加百里酚，可以保存尿液样本以防止细菌恶化。 向经过百里酚处理的样品中加入锂溶液体积标记物，然后分成两个（第一和第二）分离部分。 因此，使用第一部分，对总体积，pH /酸度，尿酸，柠檬酸盐，钠和钾进行标准常规测量和/或分析。 向第二部分加入硼酸和盐酸，然后进行铵离子，柠檬酸盐，钙，镁，磷，草酸盐和硫酸盐的标准/常规测量和/或分析。 此后，结果被绘制并与对照进行比较。

公开(公告)号：US20100227006A1

公开(公告)日：2010-09-09

申请号：US12784305

申请日：2010-05-20

申请人： Charles Y. C. Pak ,  Khashayar Sakhaee ,  Neill B. Walsdorf, SR.

发明人： Charles Y. C. Pak ,  Khashayar Sakhaee ,  Neill B. Walsdorf, SR.

IPC分类号： A61K33/10 ,  A61P19/10 ,  A61K33/08

CPC分类号： A61K33/08 ,  A61K31/19 ,  A61K33/10 ,  A61K2300/00

摘要： A composition comprising a powder mixture of potassium citrate and calcium citrate as mixtures of pure chemical salts and methods of making and using the composition are disclosed. The composition is useful for the treatment and prevention of kidney stones and osteoporosis and better delivers potassium and calcium than commonly used potassium and calcium supplements.

摘要翻译： 公开了一种组合物，其包含柠檬酸钾和柠檬酸钙作为纯化学盐的混合物的粉末混合物，以及制备和使用该组合物的方法。 该组合物可用于治疗和预防肾结石和骨质疏松症，并且比常用的钾和钙补充剂更好地输送钾和钙。

公开(公告)号：US5075499A

公开(公告)日：1991-12-24

申请号：US275046

申请日：1988-11-21

申请人： Neill B. Walsdorf ,  George Alexandrides ,  Charles Y. C. Pak

发明人： Neill B. Walsdorf ,  George Alexandrides ,  Charles Y. C. Pak

IPC分类号： A61K31/19 ,  C07C59/08 ,  C07C59/265

CPC分类号： A61K31/19 ,  C07C59/08 ,  C07C59/265

摘要： One aspect of the present invention includes the novel compound having the formula:Ca.sub.2 (OOC--CH.sub.2 --COHCOO-CH.sub.2 COO)(CH.sub.3 CHOH-COO)In another aspect of the present invention, a method is provided for the treatment of a calcium related pathology. The inventive method includes the steps of providing a pharmaceutically acceptable composition, including as the active principle the compound dicalcium citrate-lactate, and administering to an individual in need thereof a therapeutically effective amount of said pharmaceutically acceptable composition.In yet another aspect of the present invention, a process is provided for producing the compound dicalcium citrate-lactate. The inventive process comprising the steps of: (a) admixing stoichiometric quantities of citric acid and a calcium compound selected from the group consisting of calcium carbonate, calcium oxide and calcium hydroxide; (b) initiating a reaction by admixing stoichiometric quantities of lactic acid and water with said citric acid and calcium compound of step (a); (c) mixing the reactance of step (b) to produce a dense, hydrated mixture comprising calcium ions, citrate ions and lactate ions in a ratio of about 2:1:1; and (d) dehyrating the dense, hydrated mixture of step (c).

摘要翻译： 本发明的一个方面包括具有下式的新化合物：Ca2（OOC-CH2-COHCOO-CH2COO）（CH3CHOH-COO）在本发明的另一方面，提供了一种治疗钙相关病理学的方法。 本发明的方法包括提供药学上可接受的组合物的步骤，其包括作为活性成分的柠檬酸二钙 - 乳酸盐化合物，以及向有需要的个体施用治疗有效量的所述药学上可接受的组合物。 在本发明的另一方面，提供了一种制备柠檬酸二钙柠檬酸酯化合物的方法。 本发明的方法包括以下步骤：（a）混合化学计量的柠檬酸和选自碳酸钙，氧化钙和氢氧化钙的钙化合物; （b）通过将化学计量的乳酸和水与步骤（a）的所述柠檬酸和钙化合物混合来引发反应; （c）将步骤（b）的电抗混合以产生约2:1:1比例的钙离子，柠檬酸根离子和乳酸盐离子的致密的水合混合物; 和（d）使步骤（c）的致密，水合的混合物脱氢。

公开(公告)号：US4904478A

公开(公告)日：1990-02-27

申请号：US112202

申请日：1987-10-22

申请人： Neill B. Walsdorf ,  Charles Y. C. Pak

发明人： Neill B. Walsdorf ,  Charles Y. C. Pak

IPC分类号： A61K9/20 ,  A61K33/16

CPC分类号： A61K33/16 ,  A61K9/2013

摘要： A novel slow-release sodium fluoride preparation and its use. Such slow-release sodium preparation comprises carnauba wax and talc and may be used to provide a safe but effective level of fluoride in serum, optimal for the treatment of osteoporosis. Gastrointestinal side effects are minimized by limiting the amount of fluoride released in the stomach and rheumatic complications are reduced by avoiding toxic levels of fluoride is serum. The amount of fluoride absorbed is nevertheless sufficient to stimulate bone formation and prevent fractures. Thus, the maintenance of serum fluoride as encompassed in this invention, allows for a safe and effective treatment of osteoporosis.

摘要翻译： 一种新型缓释氟化钠制剂及其用途。 这种缓释钠制剂包含巴西棕榈蜡和滑石，并且可用于提供血清中安全但有效的氟化物水平，对于治疗骨质疏松症是最佳的。 通过限制在胃中释放的氟化物的量来减少胃肠道副作用，并通过避免氟化物是血清的毒性水平来降低风湿并发症。 然而，吸收的氟化物的量足以刺激骨形成并防止骨折。 因此，维持本发明所包含的血清氟化物，可以安全有效地治疗骨质疏松症。

公开(公告)号：US4888182A

公开(公告)日：1989-12-19

申请号：US019056

申请日：1987-02-26

申请人： Charles Y. C. Pak

发明人： Charles Y. C. Pak

IPC分类号： A61K31/19

CPC分类号： A61K31/19 ,  Y10S514/891

摘要： Methods and compositions useful for the treatment and prophylaxis of calcium renal stones are disclosed. The methods involve administering potassium citrate compositions to persons afflicted with or susceptible to calcium renal stone formations. A typical dosage scheme involves administering about 30 to 120 meq potassium citrate per day in divided doses. Such treatments are effective in dissolving existing calcium stones and preventing formation of new calcium stones. Moreover, the results of a comparative clinical assay indicate the potassium citrate is superior to sodium citrate in the treatment of uric acid lithiasis. Potassium citrate therapy averts calcium renal stone formation, a complication which is often associated with sodium citrate or sodium bicarbonate alkalinization therapy.

摘要翻译： 公开了用于治疗和预防钙肾结石的方法和组合物。 所述方法涉及将柠檬酸钾组合物施用于患有钙敏感性肾结石形成的患者或易受影响的人。 典型的剂量方案包括每天以分剂量施用约30至120毫克柠檬酸钾。 这种治疗有效地溶解现有的钙结石并防止形成新的钙结石。 此外，比较临床检验的结果表明柠檬酸钾在治疗尿酸结石时优于柠檬酸钠。 柠檬酸钾治疗可以避免钙肾结石形成，这种并发症通常与柠檬酸钠或碳酸氢钠碱化治疗相关。